Multi-Component Breath Alcohol Intervention Phase 3
Northeastern University · with National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT06994962
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–25 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- May 1, 2025
- Record last updated
- May 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is the third stage of a three-stage, NIH-funded study to develop and test a multi-modal intervention concerning blood/breath alcohol concentration for young adults who drink heavily. The multimodal intervention will be made up of brief telehealth counseling and psychoeducation and use of three existing mobile technologies. The brief counseling/psychoeducation and mobile technologies provide personalized feedback regarding blood or breath alcohol content. The long-term goal of use of these mobile technologies will be to facilitate moderate drinking. However, the main goals of the proposed research are to learn more about feasibility of our procedures, perceived value of the technologies and ease of use from the research participants' points of view. In this third stage of the study, the investigators will conduct a randomized controlled trial building on the formative research conducted in Stages 1 and 2.
Being studied: Alcohol-related mobile health technologies; Motivational interview and psychoeducation on blood/breath alcohol concentration; Lower tech facilitation; Higher tech facilitation; Alcohol Education; Alcohol Education Technology
Conditions: Alcohol Use; Alcohol Drinking; Drinking Behavior
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- Be between the ages of 18-25
- Be able to read English and complete study evaluations
- Report at least four days with heavy episodic drinking (i.e., 4 or more drinks for women and 5 or more drinks for men) out of the prior 30 days
- Report having consumed at least one alcoholic drink during a minimum of 12 days out of the prior 30 so that subjects will have multiple opportunities to use the moderate drinking technologies during the intervention period.
- Meet, at minimum, DSM-5 criteria for a mild alcohol use disorder (i.e., meet at least 2 diagnostic criteria)
- Self-report interest in using a smartphone app to help reduce drinking with a score of at least 3 on a 0-10 scale indicating at least a degree of openness to using technology to moderate drinking.
Exclusion Criteria
No subject may
- Have been in inpatient or intensive outpatient treatment within the past 12 months
- Have used a smartphone application to facilitate moderate drinking more than 1 time within the past 12 months
- Meet DSM-5 criteria for current substance use disorder with the exception of tobacco use disorder, mild or moderate alcohol use disorder or mild cannabis use disorder.
- History of alcohol withdrawal or medically-assisted detoxification as individuals with this history will likely be in need of more intensive treatment than is offered in this study.
- Be psychotic or otherwise severely psychiatrically disabled
- Report a history of a medical condition that would contraindicate the consumption of alcohol (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders).
Recruiting US locations
Northeastern University
Boston, MA 02115-5005
Site contact: Jade Martinez, B.S. · 617-697-7169 · ja.martinez@northeastern.edu
Study contacts (from the official record)
- Jade Martinez, B.S. · (617) 373-5132 · ja.martinez@northeastern.edu
- Allie Farone, M.S. · a.farone@northeastern.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+